Home/Filings/4/0001062993-22-023382
4//SEC Filing

Killeen Matthew 4

Accession 0001062993-22-023382

CIK 0001799850other

Filed

Dec 4, 7:00 PM ET

Accepted

Dec 5, 9:21 PM ET

Size

10.5 KB

Accession

0001062993-22-023382

Insider Transaction Report

Form 4
Period: 2022-12-01
Killeen Matthew
Chief Scientific Officer
Transactions
  • Disposition to Issuer

    Stock Option

    2022-12-01194,0490 total
    Exp: 2031-09-03Common Stock (194,049 underlying)
  • Disposition to Issuer

    Common Stock

    2022-12-015,2750 total
  • Disposition to Issuer

    Stock Option

    2022-12-0110,5500 total
    Exp: 2032-01-24Common Stock (10,550 underlying)
Footnotes (3)
  • [F1]Represents shares of common stock underlying Company Time-Vesting RSUs (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")). Each unvested RSU outstanding immediately prior to the First Effective Time (as defined in the Merger Agreement) was accelerated, cancelled and converted into the right to receive a number of Rocket common stock, rounded to the nearest whole number, equal to the number of shares of Issuer common stock underlying such Company Time-Vesting RSU multiplied by the Exchange Ratio (as defined in the Merger Agreement).
  • [F2]Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
  • [F3]Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.

Issuer

Renovacor, Inc.

CIK 0001799850

Entity typeother

Related Parties

1
  • filerCIK 0001881836

Filing Metadata

Form type
4
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 9:21 PM ET
Size
10.5 KB